Trial reportThe oncologist2019
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Trial report in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01765582 (Steam), which is not on this map. Cited by 37 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
Who cites it
37 citing papers in PubMed, 7 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Triplet chemotherapy combined with anti Epidermal Growth Factor Receptor treatment in RAS wild-type colorectal cancer: a network metanalysis.The oncologist · 2026Pooled it
- Targeted therapy in advancedBMJ (Clinical research ed.) · 2025Pooled it
- Efficacy and safety of first-line targeted and immunotherapy for metastatic colorectal cancer: a network meta-analysis.Frontiers in immunology · 2025Pooled it
- How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.Current oncology (Toronto, Ont.) · 2024Pooled it
- Chemotherapy and Targeted Therapy Strategies in Patients with Unresectable or Borderline Resectable Metastatic Colorectal Cancer: Evidence for a Lack of Focus on Resection Rates.Annals of surgical oncology · 2023Pooled it
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Pooled it
- Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials.Frontiers in oncology · 2021Pooled it
- Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial.Signal transduction and targeted therapy · 2024Trial
- Trial
- Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.World journal of surgical oncology · 2020Trial
- Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line mFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam.OncoTargets and therapy · 2026Article
- A clinical study of the CALLY index and HALP score for evaluating response to FOLFOX in colorectal cancer with lung metastases.American journal of translational research · 2026Article
- Multidimensional impact of venous thromboembolism on survival outcomes in ovarian cancer patients: deconstructing competing risks between thrombosis-related and tumor-related mortality.American journal of cancer research · 2026Article
- Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.Scientific reports · 2024Article
- FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting.Journal of gastrointestinal cancer · 2024Article
- Article
- Safety of first-line systemic therapy in patients with metastatic colorectal cancer: a network meta-analysis of randomized controlled trials.BMC cancer · 2024Article
- Novel insights into the role of translesion synthesis polymerase in DNA incorporation and bypass of 5-fluorouracil in colorectal cancer.Nucleic acids research · 2024Article
- Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.British journal of cancer · 2024Article
- Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Journal of cancer research and clinical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundFirst-line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI). STEAM (NCT01765582) assessed the efficacy of BEV plus FOLFOX/FOLFIRI (FOLFOXIRI), administered concurrently (cFOLFOXIRI-BEV) or sequentially (sFOLFOXIRI-BEV, FOLFOX-BEV alternating with FOLFIRI-BEV), versus FOLFOX-BEV for mCRC. PATIENTS AND
methodsPatients with previously untreated mCRC (
resultsORR was 72.0%, 72.8%, and 62.1% and median PFS was 11.9, 11.4, and 9.5 months with cFOLFOXIRI-BEV, sFOLFOXIRI-BEV, and FOLFOX-BEV, respectively. OS was similar between arms. ORR between cFOLFOXIRI-BEV and FOLFOX-BEV did not significantly differ (
conclusioncFOLFOXIRI-BEV and sFOLFOXIRI-BEV were well tolerated with numerically improved ORR, PFS, and liver resection rates versus FOLFOX-BEV, supporting triplet chemotherapy plus BEV as a first-line treatment option for mCRC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.